Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Advanced Accelerator Applications
Alliance for Clinical Trials in Oncology
Advanced Accelerator Applications
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Crinetics Pharmaceuticals Inc.
Exelixis